Godavari Drugs Limited has closed its trading window for all designated persons and their immediate relatives from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ending June 30, 2026. This restriction is implemented to prevent insider trading and ensure market integrity ahead of the quarterly results announcement.

The closure is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons. All connected persons and their relatives have been advised not to deal in the securities of the company during this period.

The trading window restriction is a standard compliance mechanism adopted by listed companies to prevent the misuse of unpublished price-sensitive information (UPSI). The designated persons include company directors, officers, and other employees who have access to such information.

The unaudited financial results for the quarter ending June 30, 2026, are expected to be announced shortly. The specific date of the result declaration has not been disclosed in the filing, but the trading window will reopen 48 hours after the information is made public.

Godavari Drugs Limited reported a net profit of ₹408.91 lakh for the financial year ended March 31, 2026, with revenue from operations at ₹10580.81 lakh. The company's Board of Directors approved the audited standalone financial results for the quarter and year ended March 31, 2026, at a meeting held on May 27, 2026. The statutory auditors, M/s Ayyadevara & Co., issued an unmodified opinion on the results.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a net profit of ₹129.08 lakh on revenue from operations of ₹3316.31 lakh. Total revenue for the quarter stood at ₹3330.43 lakh. In comparison, the net profit for the previous financial year ended March 31, 2025, was ₹438.00 lakh, with revenue from operations of ₹11335.01 lakh. The company reported a basic earnings per share (EPS) of ₹5.43 for FY26, compared to ₹5.82 in the previous year.

Key Appointments and AGM

Based on the Audit Committee's recommendation, the Board appointed M/s. S.K. Lahoti Associates as Internal Auditors and M/S. Bharathula & Associates as Cost Auditors for the financial year 2026-27. The appointment of the Cost Auditor is subject to ratification by shareholders at the Annual General Meeting. The Board also convened the 38th Annual General Meeting for September 25, 2026, at 03:00 p.m. via Video-Conferencing.

Capital Structure and Fund Utilization

During March 2026, the company made a preferential allotment of 25,96,935 equity shares of ₹10 each at a premium of ₹79 per share. Post-allotment, the total number of shares increased to 1,01,27,435. The company confirmed there were no deviations in the utilization of proceeds from the preferential issue during the quarter and year ended March 31, 2026. Funds raised amounting to ₹4411.73 lakh were utilized towards capital expenditure and working capital requirements.

Compliance and Disclosures

The company confirmed there were no defaults on loans and debt securities during the quarter ended March 31, 2026. The trading window for dealing in the company's securities, which closed on April 1, 2026, will remain shut until 48 hours after the declaration of the financial results. The filing was submitted by Venkatesh Achanta, Company Secretary & Compliance Officer.